Blood Bank Quality Assurance

Accurate serology cannot compensate for a specimen identification failure, an unreviewed reagent lot, an interface error, or uncontrolled component release. A blood bank quality system governs identification, testing, inventory, issue, transfusion, and final disposition through approved procedures, traceable records, assessment, and corrective action.^1,2

Oversight and quality layers

Several authorities may evaluate the same blood bank. Federal regulations set legal requirements. Accreditation standards apply when a facility holds that accreditation or has adopted the standard. The laboratory must identify every requirement that applies to its activities and build procedures that satisfy them together.

FDA identifies transfusion services among establishments that must report a qualifying deviation involving a distributed product, and federal records rules require traceability through compatibility testing, storage, distribution, and final disposition.^3,4

The current AABB edition is the 35th edition, effective April 1, 2026.¹

CAP updates its checklists annually and customizes each inspection checklist to the laboratory’s testing menu. Its public checklist catalog assigns general quality management, proficiency testing, procedures, reporting, reagents, equipment, and method verification to All Common. The Transfusion Medicine checklist adds immunohematology, compatibility testing, component storage and modification, transfusion procedures, and adverse reactions.^5,6

Three related terms describe different levels of control:

The AABB framework addresses organization, resources, equipment, suppliers and customers, process control, documents and records, deviations and adverse events, assessments, process improvement, and facilities and safety. Evidence from each area supports assessment of the others.¹

The general quality management page explains statistical control, method evaluation, proficiency-testing rules, and quality management across laboratory disciplines.

Process control in immunohematology

Each critical step requires an approved procedure, assigned responsibility, acceptance criteria, a record, and a defined response to failure. A control provides evidence only for the failure it is designed to detect. An instrument self-check documents equipment performance; reagent and specimen controls provide separate analytic evidence.

Current CMS immunohematology guidance directs laboratories to the manufacturer’s recommendations for quality control of antibody-identification panels, which generally have no separate daily requirement. A laboratory using multiple racks of reagent typing sera and cells should test a representative sample of each reagent lot in use on each day of testing and each new lot when first used. The laboratory must document every control procedure it performs.²

A negative conventional tube antiglobulin test is valid only when the required IgG-sensitized control cells react after addition. Column and solid-phase systems use their own manufacturer-specified controls. The special serologic methods page covers these method controls in detail.

Storage monitoring combines fixed requirements with facility-defined intervals. CLIA requires an audible alarm to monitor proper blood and component storage temperature over a 24-hour period and requires documented alarm inspections. Under the current AABB edition, electronic storage devices for blood and components are monitored continuously, and the temperature is recorded at least every 4 hours. AABB also requires quality-control testing of automated temperature-recording devices and alarm activation at facility-defined intervals.^2,7

Validation and change control

Validation establishes recorded evidence that a process will consistently meet predetermined specifications under its intended conditions. Verification confirms that a defined requirement has been met. Equipment qualification demonstrates installation, operation, and performance for the intended use. The evidence needed depends on the change and its risk.^1,2

Before a new or changed process supports patient testing or component release, the laboratory:

1. Defines the intended use, workflow boundaries, responsible roles, and hazards.
2. Sets acceptance criteria before collecting validation data.
3. Challenges the complete process under expected and adverse conditions, including weak, discrepant, incompatible, invalid, and downtime cases that the process is intended to handle.
4. Tests calculations, decision rules, data transfer, labels, audit trails, and manual fallback when an information system is involved.
5. Resolves failures, approves the evidence, issues controlled procedures, and trains personnel.
6. Confirms competency before independent work and monitors performance after implementation.

A new reagent lot requires acceptance under the existing validated method; the package insert and controlled procedure set the comparison scope. A new analyzer, serologic platform, electronic-crossmatch algorithm, interface, component label, temporary storage container, or major workflow change needs evidence that covers the full affected process. CAP’s All Common checklist and AABB’s process-control standards place validation and verification within the laboratory’s active quality system.^1,5,6

Controlled documents and traceable records

A document directs work. Policies state organizational rules, processes connect activities, and procedures give the steps for a task. Package inserts, job aids, forms, decision tables, and downtime instructions also require control when staff use them to perform or interpret work. Document control records the owner, approval, version, effective date, revision history, and distribution. Superseded copies are removed from points of use and handled under the retention policy.

A record shows what occurred. Blood bank records are created as work is performed and preserve the identity of the person performing each critical step, the date and time, observations, results and interpretations, reagent and supply lots when applicable, equipment, patient or donor, unit, and final disposition. Corrections must preserve the original entry and identify who changed it, when, and why.¹

CLIA requires at least 2 years of retention for test requisitions, analytic-system records, proficiency-testing records, quality-system assessment records, and reports, with specific longer rules for some records. A discontinued test procedure is retained for at least 2 years after its discontinuation.⁸

Transfusion-related immunohematology and product records follow the incorporated FDA period: retain an individual product record for at least 10 years after processing records are completed or 6 months after the latest expiration date, whichever is later. A product record with no expiration date is retained indefinitely.⁴

The retention schedule must also account for longer state, accreditation, medical-record, legal, or institutional requirements that apply to the facility.

Proficiency testing and external assessment

CLIA immunohematology proficiency-testing programs provide at least 5 samples per testing event and at least 3 events at approximately equal intervals each year. Each listed test has at least 5 challenges per event.⁹

Routine testing personnel must process proficiency samples with the regular workload, routine method, and usual number of repetitions. The laboratory must document every testing and reporting step and retain the signed attestation for at least 2 years. Before the event deadline, personnel must not discuss results with another laboratory or testing site. The laboratory must not send a sample to another laboratory for analysis that it is certified to perform.⁹

CAP recommends review of every unacceptable response, including a clerical error and an event with an acceptable overall score. The laboratory determines the cause and matches the response to the risk. An unsuccessful event calls for a comprehensive process-improvement assessment and corrective action for each unacceptable result.¹⁰

An external inspection is another assessment source. AABB and CAP assess against their current requirements and the activities within the facility’s accreditation scope. Current controlled documents and routine records show sustained compliance during the inspection.

Nonconformance investigation and corrective action

A nonconformance is a failure to meet a requirement. It may begin with a rejected specimen, failed control, temperature excursion, incorrect result, mislabeled unit, complaint, postdonation information, proficiency-testing miss, transfusion reaction, or audit finding. The response follows the affected process across departmental boundaries.

1. Contain the risk. Stop the affected activity, hold results, quarantine units, preserve specimens and records, and use the approved alternate process when service must continue.
2. Define the scope. Identify the time interval, reagent lots, equipment, software version, operators, specimens, results, components, recipients, and customers that may be affected.
3. Correct the event. Resolve the immediate result, record, unit, or service problem and notify the responsible clinical or product parties.
4. Determine causes. Examine procedure design, training, workload, environment, reagent, equipment, interface, communication, and supervision evidence.
5. Implement corrective action. Remove or control the cause, revise and approve documents, revalidate the affected process, and retrain or reassess personnel as indicated.
6. Check effectiveness. Define follow-up evidence and a review date, confirm that the process stays within criteria, and trend related events for recurrence.

A correction or remedial action resolves the immediate event. Corrective action addresses its cause. An effectiveness check supplies the evidence that the action has controlled the recurrence risk. CLIA and AABB both require documented review of corrective-action effectiveness.^1,2

External reports and notifications

Internal investigation determines whether an event also meets an external reporting trigger. The applicable authority sets the reporting deadline, the facility responsible for reporting, and the destination of the report. The table summarizes the current federal and AABB triggers.^3,7,11

FDA’s current guidance treats postdonation information as unit-suitability information outside biological product deviation reporting. The facility still follows its procedures for quarantine, consignee notification, lookback, recipient action, and disposition when the information affects a collected unit.³ The FDA fatality deadlines come from 21 CFR §606.170(b), and the current FDA reporting page provides the submission pathway.¹¹ The AABB time limits were added in the current 35th edition.⁷ State reporting, hospital patient-safety reporting, recalls, and other notifications may add requirements for a specific event.

Internal assessment and quality indicators

An internal assessment traces actual work through the full process. A unit tracer can follow one donation identification number from receipt through testing, storage, issue, transfusion, return, or discard. A patient tracer can follow the request, specimen, current and historical results, component selection, crossmatch, issue, and reaction record. The assessor compares each step with the procedure version, training and competency record, reagent and equipment record, interface or manual entry, and final disposition.

Quality indicators quantify recurring process performance. Blood bank indicators include:

• rejected or mislabeled specimens by cause and location;
• unresolved ABO discrepancies and corrected blood-group reports;
• emergency-release records completed within the facility’s required interval;
• compatibility-testing turnaround time for a defined priority;
• temperature excursions and components lost after excursions;
• component outdates and wastage by cause;
• transfusion-reaction investigations completed within the required interval;
• proficiency-testing misses and recurrence after corrective action; and
• interface, label, or manual-entry discrepancies detected before issue.

For each indicator, the quality plan defines the numerator, denominator, included population, data source, owner, review interval, threshold, and response. Trend review separates an isolated event from a recurring process weakness. Management review uses internal assessments, external inspections, complaints, proficiency testing, and quality indicators to assign resources and follow corrective action until its effectiveness is measured.^1,2,5

References

1. Association for the Advancement of Blood & Biotherapies. Standards for Blood Banks and Transfusion Services. 35th ed. AABB; 2026.
2. Centers for Medicare & Medicaid Services. State Operations Manual, Appendix C: Survey Procedures and Interpretive Guidelines for Laboratories and Laboratory Services. Rev 236. Issued January 23, 2026. Accessed August 30, 2026.
3. US Food and Drug Administration. Biological product deviations. Updated March 2, 2026. Accessed August 30, 2026.
4. Electronic Code of Federal Regulations. 21 CFR §606.160: Records. Updated through August 27, 2026. Accessed August 30, 2026.
5. College of American Pathologists. Accreditation checklists. Updated June 22, 2026. Accessed August 30, 2026.
6. College of American Pathologists. CAP Accreditation Checklists: 2025 Edition. CAP; 2025. Accessed August 30, 2026.
7. Association for the Advancement of Blood & Biotherapies. Significant Changes and Response to Comments Received to the 35th Edition of Standards for Blood Banks and Transfusion Services. Published February 2026.
8. Electronic Code of Federal Regulations. 42 CFR §493.1105: Standard: Retention requirements. Updated through August 27, 2026. Accessed August 30, 2026.
9. Electronic Code of Federal Regulations. 42 CFR §493.801: Condition: Enrollment and testing of samples; 42 CFR §493.959: Immunohematology. Updated through August 27, 2026. Accessed August 30, 2026.
10. College of American Pathologists. Proficiency testing/external quality assessment frequently asked questions. Updated June 23, 2026. Accessed August 30, 2026.
11. US Food and Drug Administration. Transfusion/donation fatalities. Accessed August 30, 2026.